Lovastatin and Rolipram

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Lovastatin and Rolipram

Postby scoobyjude » Fri Dec 19, 2008 8:51 pm

Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis.Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK.
Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425, USA.

Drug combination therapies for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS) are gaining momentum over monotherapy. Over the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression of MS in affected individuals via different mechanisms of action. In this study, we evaluated the effectiveness of lovastatin (LOV) and rolipram (RLP) in combination therapy to promote neurorepair in an inflammatory CNS demyelination model of MS, experimental autoimmune encephalomyelitis (EAE). Combination treatment with suboptimal doses of these drugs in an established case of EAE (clinical disease score > or = 2.0) significantly attenuated the infiltration of inflammatory cells and protected myelin sheath and axonal integrity in the CNS. It was accompanied with elevated level of cyclic AMP and activation of its associated protein kinase A. Interestingly, combination treatment with these drugs impeded neurodegeneration and promoted neurorepair in established EAE animals (clinical disease score > or = 3.5) as verified by quantitative real-time polymerase chain reaction, immunohistochemistry and electron microscopic analyses. These effects of combination therapy were minimal and/or absent with either drug alone in these settings. Together, these data suggest that combination therapy with LOV and RLP has the potential to provide neuroprotection and promote neurorepair in MS, and may have uses in other related CNS demyelinating diseases.

PMID: 18720408 [PubMed - in process]
User avatar
Family Elder
Posts: 516
Joined: Sat Feb 18, 2006 4:00 pm
Location: suburb of Chicago, IL USA


Postby CureOrBust » Sat Dec 20, 2008 6:32 am

hmmm... they trialled Rolipram by itself with MS (Phase II), and from what I could find, it was aborted because they could not raise the doses in humans to levels that were effective (when compared to the levels found effective on mice with EAE).

These "suboptimal doses" would be interesting to hear what they actually were? i.e how sub-clinical were they in comparison to clinical doses?

The other interesting thing
established case of EAE (clinical disease score > or = 2.0)
Is there a Mouse EDSS?
User avatar
Family Elder
Posts: 3341
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service